Málta - angol - Medicines Authority

accord healthcare limited - fludarabine phosphate - concentrate for solution for infusion or injection - fludarabine phosphate 25 mg/ml - antineoplastic agents

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - fludarabine phosphate, quantity: 50 mg - injection, powder for - excipient ingredients: mannitol; sodium hydroxide - treatment of b-cell chronic lymphocytic leukaemia

Írország - angol - HPRA (Health Products Regulatory Authority)

genzyme europe b.v. - fludarabine phosphate - powder for solution for injection/infusion - 50 milligram(s) - purine analogues; fludarabine

Írország - angol - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - fludarabine phosphate - concentrate for solution for injection/infusion - 25 milligram(s)/millilitre - purine analogues; fludarabine

Írország - angol - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - fludarabine phosphate - concentrate for solution for injection/infusion - 25 milligram(s)/millilitre - purine analogues; fludarabine

Egyesült Államok - angol - NLM (National Library of Medicine)

hospira, inc. - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate 50 mg in 2 ml - fludarabine phosphate for injection, usp is indicated for the treatment of adult patients with b-cell chronic lymphocytic leukemia (cll) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. the safety and effectiveness of fludarabine phosphate, usp in previously untreated or non-refractory patients with cll have not been established. fludarabine phosphate, usp is contraindicated in those patients who are hypersensitive to this drug or its components.

Egyesült Államok - angol - NLM (National Library of Medicine)

sagent pharmaceuticals - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate 25 mg in 1 ml - fludarabine phosphate for injection, usp is indicated for the treatment of adult patients with b-cell chronic lymphocytic leukemia (cll) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. the safety and effectiveness of fludarabine phosphate for injection, usp in previously untreated or non-refractory patients with cll have not been established. fludarabine phosphate for injection is contraindicated in those patients who are hypersensitive to this drug or its components.

Egyesült Államok - angol - NLM (National Library of Medicine)

actavis pharma, inc. - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate 50 mg in 2 ml - fludarabine phosphate for injection is indicated for the treatment of adult patients with b-cell chronic lymphocytic leukemia (cll) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. the safety and effectiveness of fludarabine phosphate for injection in previously untreated or non-refractory patients with cll have not been established. fludarabine phosphate for injection is contraindicated in those patients who are hypersensitive to this drug or its components.

Egyesült Államok - angol - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. (dba leucadia pharmaceuticals) - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate 25 mg in 1 ml - fludarabine phosphate for injection, usp is indicated for the treatment of adult patients with b-cell chronic lymphocytic leukemia (cll) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. the safety and effectiveness of fludarabine phosphate for injection, usp in previously untreated or non-refractory patients with cll have not been established. fludarabine phosphate for injection is contraindicated in those patients who are hypersensitive to this drug or its components.

Szingapúr - angol - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - influenza virus (sh) a/thailand/8/2022 (h3n2) - like strain; influenza virus (sh) a/victoria/4897/2022 (h1n1)pdm09-like strain; influenza virus (sh) b/austria/1359417/2021 - like strain; influenza virus (sh) b/phuket/3073/2013-like strain - injection, suspension - influenza virus (sh) a/thailand/8/2022 (h3n2) - like strain 15mcg ha/0.5ml; influenza virus (sh) a/victoria/4897/2022 (h1n1)pdm09-like strain 15mcg ha/0.5ml; influenza virus (sh) b/austria/1359417/2021 - like strain 15mcg ha/0.5ml; influenza virus (sh) b/phuket/3073/2013-like strain 15mcg ha/0.5ml